XNAS · ALXO
+0.51% · +$0.0100 · Vol 698.7K
Market closed · last close 4:00 PM ET · price as of 16:01:49 ET
ALX Oncology Holdings Inc. Common Stock

ALX Oncology Holdings Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.97
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
ALXO
ALX Oncology Holdings Inc. Common Stock
Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

71/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALXO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALXO catalysts
About ALX Oncology Holdings Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
48
Country
US

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.93
Day high
$2.00
Day low
$1.91
Previous close
$1.96
52W high
$2.60
-24.23% from high
52W low
$0.8320
64% of range
Market cap
$271M
EPS
$-1.2000
Beta
0.87
Shares out
138.3M
Volume
698.7K
0.67× rel vol
Avg volume
1M
VWAP
$1.96
Price history computed in-house
1W
+2.07%
1M
-6.19%
3M
-1.01%
1Y
+102.90%
YTD
+74.34%
SMA 50 $1.91 · above
SMA 200 $1.78 · above
52W position 64%

ALXO overview

Veridion Score
71
Daily close · 2026-08-17
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALXO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALXO Form 4 filings
Public disclosures

Congress activity in ALXO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALXO in the cached public ledger.

Federal contracts

ALXO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALXO in this window.
Lobbying spend

ALXO lobbying filings, year to date.

Registered lobbying filings matched to ALX Oncology Holdings Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALXO in this window.
Loading news for ALXO
Analyst ratings
Sovereign unlock shows live analyst consensus for ALXO.
Options
Sovereign unlock shows live options positioning for ALXO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.